Antibiotic time-lag combination therapy with fosfomycin for postoperative intra-abdominal abscesses

Kusachi, Shozo; Nagao, Jirō; Saida, Yoshihisa; Watanabe, Manabu; Okamoto, Yasushi; Asai, Koji; Nakamura, Yoichi; Enomoto, Toshiyuki; Arima, Yoichi; Kiribayashi, Takaharu; Watanabe, Ryohei; Saito, Tomoaki; Uramatsu, Masashi; Sato, Junko

doi:10.1007/s10156-010-0167-0

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, fosfomycin is being evaluated in combination with other antibiotics for MDR or XDR infections (NCT01297894, NCT02142751, and NCT00871104). Table 5 summarizes the characteristics and outcomes of contemporary studies regarding the effectiveness of fosfomycin for the treatment of infections due to MDR bacteria (219,220,(240)(241)(242)(243)(244)(245)(246). Fosfomycin was prescribed for several indications in variable doses and always in combination with other antibiotics.…”

Section: Non-urinary Tract Infectionsmentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

Section: Non-urinary Tract Infectionsmentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[40][41][42][43] Based on reports, fosfomycin can break up biofilms to enhance the permeability of other antibiotics. 44…”

Section: Antimicrobial Activitymentioning

confidence: 99%

The revival of fosfomycin

Michalopoulos

Livaditis

Gougoutas

2011

International Journal of Infectious Diseases

341

296

View full text Add to dashboard Cite

Fosfomycin, originally named phosphonomycin, was discovered in Spain in 1969. There are three forms of fosfomycin: fosfomycin tromethamine (a soluble salt) and fosfomycin calcium for oral use, and fosfomycin disodium for intravenous use. Fosfomycin is a bactericidal antibiotic that interferes with cell wall synthesis in both Gram-positive and Gram-negative bacteria by inhibiting the initial step involving phosphoenolpyruvate synthetase. It has a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. It is highly active against Gram-positive pathogens such as Staphylococcus aureus and Enterococcus, and against Gram-negative bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae. Its unique mechanism of action may provide a synergistic effect to other classes of antibiotics including beta-lactams, aminoglycosides, and fluoroquinolones. Oral fosfomycin is mainly used in the treatment of urinary tract infections, particularly those caused by Escherichia coli and Enterococcus faecalis. Intravenous fosfomycin has been administered in combination with other antibiotics for the treatment of nosocomial infections due to multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria. Fosfomycin has good distribution into tissues, achieving clinically relevant concentrations in serum, kidneys, bladder wall, prostate, lungs, inflamed tissues, bone, cerebrospinal fluid, abscess fluid, and heart valves. Fosfomycin is well tolerated, with a low incidence of adverse events. Further randomized controlled trials are needed in order to evaluate the efficacy of intravenous fosfomycin for the management of nosocomial infections due to MDR pathogens.

show abstract

“…Fosfomycin can penetrate multilayer biofilms and studies suggest that the penetration into the cells occurs in the low growth rate phase [30]. Fosfomycin can also disintegrate biofilms to enhance the permeability of other antibiotics, as seen with studies on gram-negative bacteria [32]. However, there is controversy over whether this occurs in MRSA [23].…”

Section: Discussionmentioning

confidence: 99%

Fosfomycin Addition to Poly(D,L-Lactide) Coating Does Not Affect Prophylaxis Efficacy in Rat Implant-Related Infection Model, But That of Gentamicin Does

Gülcü¹,

Akman²,

Demirkan³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Gentamicin is the preferred antimicrobial agent used in implant coating for the prevention of implant-related infections (IRI). However, the present heavy local and systemic administration of gentamicin can lead to increased resistance, which has made its future use uncertain, together with related preventive technologies. Fosfomycin is an alternative antimicrobial agent that lacks the cross-resistance presented by other classes of antibiotics. We evaluated the efficacy of prophylaxis of 10% fosfomycin-containing poly(D,L-lactide) (PDL) coated K-wires in a rat IRI model and compared it with uncoated (Control 1), PDL-coated (Control 2), and 10% gentamicin-containing PDL-coated groups with a single layer of coating. Stainless steel K-wires were implanted and methicillin-resistant Staphylococcus aureus (ATCC 43300) suspensions (103 CFU/10 μl) were injected into a cavity in the left tibiae. Thereafter, K-wires were removed and cultured in tryptic soy broth and then 5% sheep blood agar mediums. Sliced sections were removed from the tibiae, stained with hematoxylin-eosin, and semi-quantitatively evaluated with X-rays. The addition of fosfomycin into PDL did not affect the X-ray and histopathological evaluation scores; however, the addition of gentamicin lowered them. The addition of gentamicin showed a protective effect after the 28th day of X-ray evaluations. PDL-only coating provided no protection, while adding fosfomycin to PDL offered a 20% level protection and adding gentamicin offered 80%. Furthermore, there were 103 CFU level growths in the gentamicin-added group, while the other groups had 105. Thus, the addition of fosfomycin to PDL does not affect the efficacy of prophylaxis, but the addition of gentamicin does. We therefore do not advise the use of fosfomycin as a single antimicrobial agent in coating for IRI prophylaxis.

show abstract

Antibiotic time-lag combination therapy with fosfomycin for postoperative intra-abdominal abscesses

Cited by 10 publications

References 14 publications

Fosfomycin

Fosfomycin

The revival of fosfomycin

Fosfomycin Addition to Poly(D,L-Lactide) Coating Does Not Affect Prophylaxis Efficacy in Rat Implant-Related Infection Model, But That of Gentamicin Does

Contact Info

Product

Resources

About